1. Home
  2. News
  3. Immutep Ltd
  4. Recruitment of head & neck cancer patients completed for ph2
More Immutep Ltd news
Immutep LtdASX: IMM

Recruitment of head & neck cancer patients completed for ph2

Jan 6, 2021 at 10:54 PM EST · Issued by Immutep Ltd

Filed with ASX · Jan 6, 2021 at 10:54 PM EST · 2 pages · English

On 6ix: 6ix.com/news/recruitment-of-head-and-neck-cancer-patients-completed-for-ph2

Immutep Ltd on 6ix

Earlier from Immutep

  • Immutep granted US patent for eftilagimod alpha with a PD-1Dec 29, 2020
  • Immutep Upscales Efti ManufacturingDec 16, 2020
  • Immuteps partner EOC pharma to start Ph II trial in MBCDec 9, 2020
  • Proposed issue of Securities - IMMNov 18, 2020
  • Pause in TradingNov 17, 2020

Later from Immutep

  • Ulcerative Colitis Phase II Study of GSK2831781 DiscontinuedJan 21, 2021
  • Phase II study for eftilagimod alpha in COVID-19 advancesJan 26, 2021
  • Immutep secures second US patent grant for eftilagimod alphaMar 9, 2021
  • S&P DJI Announces March 2021 Quarterly RebalanceMar 12, 2021
  • Immutep collaborates with MSD for phase 2b head & neck trialMar 15, 2021
All Immutep news releases↗

Follow Immutep into a list and get an email when it puts out news.

Follow Immutep
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer